Abstract:Introduction: GBM is the most common primary malignancy of the CNS. Historically pre-clinical models have failed to predict response in humans, despite promising preclinical data. Moreover, current models seldom incorporate surgical resection and/or standard of care chemotherapy treatment. These models also commonly employ young animals exclusively, whose immune contexture differs from older patients. We therefore sought to establish an improved, orthotopic, preclinical GBM model, which better recapitulates patient response to standard-of-care and targeted treatments. Methods: NFpp10a-Luc2 GBM cells were orthotopically implanted into C57BL/6-mice (aged[>18months] and young[6-8weeks]) and weekly bioluminescence imaging performed to monitor tumor growth. Overall survival (OS) and tumor growth were assessed in response to (1) Surgical Resection, (2) Temozolomide (TMZ) (3) anti-PD1 (4) neoadjuvant anti-PD1 and (5) Regorafenib (REGO) therapy. Tissue collected post-mortem underwent bulk RNA sequencing followed by analysis via microenvironment cell population counter (MCP) and gene set enrichment (GSEA) to determine changes in the GBM-TME following treatment. Results: We demonstrated OS advantage in aged mice undergoing surgical resection (Resection:33.5 days vs Non-Resection: 18 days; p=0.0166) and observed age to be a significant prognostic factor (Young:62 days vs Aged: 22 days; p=0.0002). Subsequently, we observed that TMZ and anti-PD1 monotherapies had no impact on NFpp10-Luc2 growth (p=0.9001, p=0.7933) or survival (p=0.3035, p=0.6328). Neoadjuvant anti-PD1 treated mice demonstrated no significant survival advantage compared to IgG control (33 days vs 35 days; p=0.9429). Lastly, REGO treatment demonstrated a trend towards improved OS vs Vehicle (p=0.096). MCP analysis revealed both neoadjuvant anti-PD1 and REGO treatment induced influx of CD8+ T cells, B cells and monocytes into the TME, with neoadjuvant anti-PD1 associated with an upregulation of CXCR3 (p=0.0045). Conclusions: We have, for the first time, established and characterized response of the NFpp10a-C57BL/6 model to surgical resection, TMZ, anti-PD1 and REGO therapy in both young and aged mice. We have shown the model is markedly insensitive to intervention with chemotherapy and immune checkpoint therapy, mirroring what is seen clinically in patients. The model may therefore be employed in future pre-clinical studies to guide clinical trials in the setting of mesenchymal GBM. Citation Format: Kate Connor, Kieron White, James Clerkin, Kieron Sweeney, Liam Shiels, Thomas van Brussel, Ingrid Arijs, Diether Lambrechts, Gautam Shankar, Frederik de Smet, Stephen G. Maher, Laure Marignol, Patrick Dicker, Jochen Prehn, David O'Brien, Annette T. Byrne. Establishing a novel clinically relevant disease model of glioblastoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 1441.

Correction: The biotoxin BMAA promotes dysfunction via distinct mechanisms in neuroblastoma and glioblastoma cells

Corrigendum for “A Novel Kinase Subverts Aluminium Resistance by Boosting Ornithine Decarboxylase‐dependent Putrescine Biosynthesis”

The biotoxin BMAA promotes mesenchymal transition in neuroblastoma cells

Correction To: Therapeutic Efficacy, Pharmacokinetic Profiles, and Toxicological Activities of Humanized Antibody-Drug Conjugate Zt/g4-MMAE Targeting RON Receptor Tyrosine Kinase for Cancer Therapy

Correction: BCR-Net: A deep learning framework to predict breast cancer recurrence from histopathology images

Retraction Note: Reprogramming glioblastoma multiforme cells into neurons by protein kinase inhibitors

RETRACTION: NGF Protects Neuroblastoma Cells Against β-Amyloid-Induced Apoptosis via the Nrf2/HO-1 pathway

Erratum: Correction: Phosphorylation of proliferating cell nuclear antigen promotes cancer progression by activating the ATM/Akt/GSK3β/Snail signaling pathway (The Journal of biological chemistry (2019) 294 17 (7037-7045))

Correction: Corrigendum: Selective Killing of Cancer Cells by a Small Molecule Targeting the Stress Response to ROS

Corrigendum to “the Neuroprotective Effect of Deep Brain Stimulation at Nucleus Basalis of Meynert in Transgenic Mice with Alzheimer’s Disease” [brain Stimul 12 (2019) 161–174]

[Corrigendum] Inhibition of BTK protects lungs from trauma-hemorrhagic shock-induced injury in rats

Erratum: Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells

Immu-58. Bcat1 Targeted Metabolic Reprogramming Plays Critical Roles In Modulating Myeloid Derived Suppressor Cell Function In Glioblastoma

Erratum: Mesenchymal Stem Cell-Based NK4 Gene Therapy in Nude Mice Bearing Gastric Cancer Xenografts [Corrigendum]

Author Correction: Neuroprotectants Attenuate Hypobaric Hypoxia-Induced Brain Injuries in Cynomolgus Monkeys

Corrigendum: Myelomodulatory treatments augment the therapeutic benefit of oncolytic viroimmunotherapy in murine models of malignant peripheral nerve sheath tumors

Abstract 1441: Establishing a novel clinically relevant disease model of glioblastoma

Erratum: Molecular diversity of astrocytes with implications for neurological disorders (Proceedings of the National Academy of Sciencs of the United States of America (June 1 …

Correction: Alves et al. WNK2 Inhibits Autophagic Flux in Human Glioblastoma Cell Line. Cells 2020, 9, 485

Publisher Correction: Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumors

Correction: Krayem et al. Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance. Cancers 2020, 12, 512